Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KAND 567

Drug Profile

KAND 567

Alternative Names: AZD-8797; KAN-0440567; KAND-567

Latest Information Update: 26 Nov 2020

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Kancera
  • Class Amines; Analgesics; Anti-inflammatories; Antineoplastics; Cardiovascular therapies; Neuroprotectants; Organic sulfur compounds; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Chemokine CXCL13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II SARS-CoV-2 acute respiratory disease
  • Phase I Myocardial infarction
  • Preclinical Cardiovascular disorders; Spinal cord injuries
  • No development reported Autoimmune disorders; Breast cancer; Cancer; Cancer pain; Pancreatic cancer
  • Discontinued Multiple myeloma

Most Recent Events

  • 28 Sep 2020 No recent reports of development identified for preclinical development in Pancreatic-cancer in Sweden (PO)
  • 10 Jul 2020 Swedish Medical Products Agency approves clinical trial application for KAND 567 in COVID-2019 infections
  • 02 Jul 2020 Phase-II clinical trials in SARS-COV-2 acute respiratory disease (Combination therapy) in Sweden (PO) (EudraCT2020-002322-85)

Development Overview

Introduction

KAND 567 (previously AZD 8797) is a small-molecule antagonist of the Fractalkine receptor CX3CR1, is being developed by Kancera, under an agreement with Acturum Life Science and in collaboration with Uppsala University, for the oral treatment of solid tumours, including pancreatic cancer and breast cancer, and for cancer pain, auto-immune disorders and for SARS-COV-2 acute respiratory disease. Fractalkine is an immune-modulating factor, which transmits signals via the CX3CR1 receptor, thereby controlling the function of immune cells and cancer cells. Phase I development is underway for cancer and related pain, myocardial infarction and auto-immune disorders in the Netherlands and Sweden. Preclinical development is underway for pancreatic cancer, cardiovascular disorders, spinal cord injuries and breast cancer in Sweden. Clinical development for SARS-COV-2 acute respiratory disease is underway in Sweden.

Preclinical development for multiple myeloma was underway in the UK. However, development in this indication was discontinued.

AstraZeneca originally developed KAND 567 against multiple sclerosis. Acturum Life Science later acquired the rights to the project from AstraZeneca.

As at April 2020, no recent reports of development had been identified for preclinical development in Breast-cancer in Sweden (PO).

As at June 2020, no recent reports of development had been identified for phase-I development in Autoimmune-disorders in Netherlands (PO), phase-I development in Cancer in Netherlands (PO), phase-I development in Cancer-pain in Netherlands (PO).

As at September 2020, no recent reports of development had been identified for preclinical development in Pancreatic-cancer in Sweden (PO).

Company Agreements

In September 2017, Kancera entered into a development and manufacturing agreement with Recipharm, for the manufacture of KAND 567. As part of the collaboration, Recipharm will develop the preparation that is required for effective release of KAND 567 from the capsules, as well as manufacturing the pharmaceutical product. The work is intended to be performed at Recipharm’s development facility in Solna [1]

According to the Kancera first quarter of 2016 report, Kancera entered into an agreement with Acturum Life Science AB to evaluate and further develop KAND 567, in 2015. Under the agreement, Kancera has the right to evaluate KAND 567 in preclinical studies and then to acquire the project. The agreement entails no expenses for Kancera apart from investments in the patent portfolio and in the scientific evaluation. Kancera announced that it has chosen to acquire the project. If the acquisition goes through, following preclinical studies phase, the total payment to Acturum will consist of 6 million Kancera shares divided into three tranches, which are due at pre-defined success-milestones. Both companies will share the risk in product development through the first study in man.

Acturum Life Science acquired the rights to the KAND 567 project from AstraZeneca as part of Acturum’s acquisition of the research facility in Södertälje. However, AstraZeneca has retained the rights to develop Fractalkine inhibitors against respiratory diseases.

Key Development Milestones

In July 2020, Kancera initiated a phase II trial to evaluate efficacy, safety, tolerability and pharmacokinetics of KAND 567 in patients with SARS-COV-2 acute respiratory disease (KAN0006; EudraCT2020-002322-85). The open label trial intends to enroll 40 patients in Sweden. Patients will be administered with either oral KAND 567 as capsule in combination with the best standard treatment or only the best standard treatment. Earlier the Swedish Medical Products Agency had approved the clinical trial application (CTA) to conduct the phase II trial. Kancera had submitted an application to the Swedish Medicines Agency in May 2020 [2] [3] [4] .

In March 2020, Kancera released positive data from the final part of phase Ib trial and evaluated safety, tolerability in 17 healthy volunteers with 6 volunteers in placebo. A total of 92 healthy volunteers have been tested in phase I study [5] . In June 2019, Kancera initiated a phase Ib trial to evaluate the safety, tolerance and exposure of KAND 567 administered intravenously in 27 healthy volunteers in Sweden and Finald. The start of the trial triggered the third and final payment in the form of two million shares to Acturum, in mid-July, in accordance with the ongoing agreement between the two companies [6] [7] [8] . Earlier in May 2019, Medical Products Agency and the Ethics Committee had approved the application for the study. In August 2019, first exploratory part of the trial was completed and company announced positive interim results in healthy participants. The company also announced that a supplemental application would be filed to the Medical Products Agency, for the approval of an adjusted ratio of infusion rate to concentration of KAND 567. The protocol was amended to avoid local irritation at the infusion site, observed in the interim analysis [9] [10] [6] [11] . The company applied for permission by submitting a supplemental dosing strategy to Swedish Medical Products Agency to adjust ratio of infusion rate to concentration of KAND 567. The Swedish Medical Products Agency advised the company to submit supplementary information and a new application permit in order to continue the study. In February 2020, Kancera received approval from the Finnish Medicines Agency Fimea and the Ethics Committee to start the final part of the phase Ib program for KAND 567 [12] . Earlier in November 2019, Kancera reported that it had compiled the requested information and prepared a new application, but in order to maintain the timeline for a phase IIa trial the company had elected to apply for the final part of the study in Finland instead of as previously planned in Sweden. In December 2019, company released analysis of blood samples from healthy participants [13] [14] [6] [9] .

In February 2019, Kancera completed a phase Ia trial that evaluated the safety, tolerability and pharmacokinetic properties of KAND 567 in healthy volunteers. The randomised, double-blind, placebo-controlled trial was initiated in May 2017 and enrolled 82 healthy participants, in the Netherlands. First part of the study is single dose part of the study in which increasing single doses (8-2500 mg) of KAND 567 was given to groups of 62 healthy volunteers with and without food on different occasions. In the second part which is multiple dose part of the study, KAND 567 was given in increasing doses up to 7 days (300 - 800 mg twice a day). The second part of the study was commenced in September 2017 [15] [16] . In February 2018, Kancera announced positive results from this study. Results showed that KAND 567 blocks the fractalkine system by reducing the number of fractalkine receptors on the surface of immune cells. In February 2019, results from the 66 evaluable patients were released by the company [17] [18] [19] .

In June 2020, Kancera released preclinical data showing nerve-protective effect of KAND 567 in disease model of spinal cord injury [2] .

In January 2019, Kancera released safety data for the preclinical toxicological study of intravenous KAND 567 [11] .

In preclinical studies, KAND 567 exhibited an anti-inflammatory effect and protected blood vessels in atherosclerosis [20]

KAND 567 showed cardiovascular protection properties in preclinical disease models [19] . KAND 567 was evaluated for efficacy and safety in a disease model of myocardial infarction and in a toxicological GLP study, respectively. The efficacy study showed that lower doses than expected provided a significant cardio-protective effect. Preliminary results from the toxicology study provided evidence pointing towards the safety of the calculated effective dose of KAND 567 [21] .

Earlier, in April 2017, Kancera applied to the relevant authorities in the Netherlands for authorization for clinical trials. The Medical Ethics Committee (METC) at the University Medical Center in Groningen, the Netherlands, has given approval for the initiation of the phase I study (Kancera pipeline, December 2017).

According to the Kancera company website, as of August 2016, the company intends to apply for orphan drug designation for KAND 567.

In preclinical studies, KAND 567 counteracted the onset of autoimmune disorders, as well as neuritis and pain in connection with chemotherapy against cancer [1] .

Financing information

Kancera, in November 2019, received a bridge financing of approximately SEK 14.0 million. The company intends to use the proceeds from this financing for completing the phase Ib trial of KAND 567. The company expects to receive new issue units of approximately SEK 61.4 million during first quarter of 2020.The funds from this financing will be used to carry phase IIa trial [14]

Patent Information

In August 2019, Kancera reported that two patent applications related to KAND 567, entered the international phase, at the conclusion of the second quarter of 2019. The patent applications were filed earlier in July 2018, as reported by Kancera [6] [22] . Patents contains use of KAND 567 for the treatment and prevention of hyperinflammation in viral infections [3] .

Drug Properties & Chemical Synopsis

  • Route of administration IV, PO
  • Formulation Capsule, unspecified
  • Class Amines, Analgesics, Anti-inflammatories, Antineoplastics, Cardiovascular therapies, Neuroprotectants, Organic sulfur compounds, Pyrimidines, Small molecules, Thiazoles
  • Target Chemokine CXCL13
  • Mechanism of Action Chemokine CXCL13 inhibitors
  • WHO ATC code

    C01 (Cardiac Therapy)

    J05A-X (Other antivirals)

    L01 (Antineoplastic Agents)

    N02 (Analgesics)

    N07X (Other Nervous System Drugs)

  • EPhMRA code

    C1 (Cardiac Therapy)

    J5B9 (Antivirals, others)

    L1 (Antineoplastics)

    N2 (Analgesics)

    N7X (All other CNS drugs)

  • Chemical name (2R)-2-[[2-amino-5-[(1S)-1-phenylethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol
  • Molecular formula C19 H25 N5 O S2
  • Chemical Structure

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
Autoimmune disorders - - No development reported (I) Netherlands PO / unspecified Kancera 28 Jun 2020
Breast cancer - - No development reported (Preclinical) Sweden PO / unspecified Kancera 28 Apr 2020
Cancer - - No development reported (I) Netherlands PO / unspecified Kancera 28 Jun 2020
Cancer pain - - No development reported (I) Netherlands PO / unspecified Kancera 28 Jun 2020
Cardiovascular disorders Cardiovascular inflammation - Preclinical Sweden PO / unspecified Kancera 30 Jun 2018
Multiple myeloma - - Discontinued (Preclinical) United Kingdom PO / unspecified AstraZeneca 15 Aug 2016
Myocardial infarction - In volunteers Phase I Finland, Sweden IV / unspecified Kancera 04 Jun 2019
Pancreatic cancer - - No development reported (Preclinical) Sweden PO / unspecified Kancera 28 Sep 2020
SARS-CoV-2 acute respiratory disease - Combination therapy Phase II Sweden PO / Capsule Kancera 02 Jul 2020
Spinal cord injuries - - Preclinical Sweden unspecified / unspecified Kancera 15 Jun 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
AstraZeneca Originator United-Kingdom
Acturum Life Sciences Owner Sweden
Uppsala University Collaborator Sweden
Karolinska Institute Collaborator Sweden
Kancera Collaborator Sweden
Recipharm Collaborator Sweden

Scientific Summary

Pharmacokinetics

Results of a phase Ia study showed that efficient absorption of KAND 567 from the intestine to the blood independent of food was observed. KAND 567 stays in the blood long enough in humans to allow dosage one to two times a day. The randomized, double-blind, placebo-controlled trial assessed KAND 567 for the treatment of cancer, cancer pain and auto-immune disorders in 62 healthy participants [18] [16] .

Results from final part of the phase Ib study involving 17 healthy volunteers versus 6 in placebo, showed desired plasma concentration of KAND 567 upon intravenous infusion similar to that found in interim results from a phase Ib study in 27 evaluable volunteers. Desired effect on the immune system reaches the heart within two minutes of the start of the intravenous infusion [5] [6] [8] .

Adverse Events

Results from final part of phase Ib study involving 17 healthy volunteers versus 6 healthy volunteers in placebo, of KAND 567 was found to be well tolerated by intravenous administration and it complements the phase Ia study data. Interim results from a phase Ib study in 27 evaluable volunteers, showed that KAND 567 was safe and well-tolerated, when administered as a short-term intravenous infusion, in the initial, exploratory trial phase. The follow-up part of the study however, revealed incidences of local irritation at the infusion site, when the infusion was administered for an extended period [5] [6] [8] .

Results from the single dose part and the multiple dose part of a phase Ia study showed that KAND 567 was safe and well tolerated. In single dose part of the study, no clinically relevant side effects were observed in KAND 567 treated patients in single doses up to 2500 mg. In multiple dose part of the study, KAND 567 is safe and well-tolerated up to 500 mg twice daily for 7 days with five to ten times higher plasma levels achieved than the calculated effective level for therapeutic effect in humans. Gastric side effects in the form of diarrhoea and a clinically relevant increase in markers for hepatic impairment were observed at a dose of 800 mg twice a day (total 1600 mg). However, markers for hepatic impairment returned to normal level after the end of treatment. No other clinically relevant side effects of KAND567 were noted. The randomized, double-blind, placebo-controlled trial assessed KAND 567 for the treatment of cancer, cancer pain and auto-immune disorders in 62 healthy participants [19] [18] [16] .

In preclinical toxicological study, administration of intravenous KAND567 demonstrated favourable safety profile [11] .

Pharmacodynamics

Results from a phase Ia study showed that decrease in the number of fractalkine receptors on the cell surface of specific immune cells such as NK cells, T cells and monocytes was observed in KAND 567 (300 mg, twice daily) treated patients. Invitro studies in whole blood showed that KAND 567 blocks the fractalkine signal in human immune cells at low concentrations. These findings showed that KAND567 blocks the fractalkine system through two co-operating mechanisms. The randomized, double-blind, placebo-controlled trial assessed KAND 567 for the treatment of cancer, cancer pain and auto-immune disorders in 62 healthy participants [19] [18] [16] .

Preclinical studies in animal models showed that KAND 567 has shown cardiovascular protective anti-inflammatory properties as evident by significant reduction in infarct size (internal report), stabilisation of vascular plaque (internal report) that can cause infarction and reversal of relapse (restenosis) after widening of the coronary artery with so-called vessel stents [18] .

Preclinical studies in disease model of spinal cord injury showed that a single daily administration of KAND 567 improved the healing of spinal cord injury. An analysis of spinal cord tissue showed that KAND 567 prevented nerve cells from dying. The nerve-protective effect was due to KAND 567 suppressing the hyperinflammation that occurs after spinal cord injury. This was evident from a decreased level of the inflammation driving cytokines IL-1beta and IL-6 in the spinal cord [2] .

Immunogenicity

Summary

In phase Ib trial, the analysis of blood samples demonstrated lowered levels of an established and clinically relevant immune marker in the participants treated with KAND 567 which showed that blockage of the Fractalkine system led to a significant decrease in activity of two types of immune cells involved in inflammatory diseases and the effect was observed after two hours of infusion [13] [8] .

Therapeutic Trials

The analysis of immune cells in the blood from the phase Ia trial involving 66 evaluable patients demonstrated a statistically significant activation of the fractalkine system in the lymphoma patients compared to a group of healthy controls [17] .

Future Events

Expected Date Event Type Description Updated
30 Jun 2020 Trial Update Kancera plans a phase IIa trial for Myocardial infarction (IV) (PO) in the second quarter of 2020 (700302310) [14] 06 Dec 2019
30 Jun 2020 Regulatory Status Kancera announces intention to submit application to start phase II trial for Myocardial infarction during second quarter of 2020 [5] 17 Mar 2020
30 Jun 2019 Regulatory Status Kancera plans to file regulatory application with the Japanese Pharmaceuticals and Medical Devices Agency for a IIa trial in Myocardial infarction in the second quarter of 2019 [21] 28 Nov 2018
30 Jun 2019 Trial Update Kancera plans a phase Ib trial in healthy volunteers in Sweden, in June 2019 (IV) [11] 26 Jun 2019
31 Mar 2019 Regulatory Status Kancera plans to file regulatory application with the Medical Products Agency for a phase Ib trial in healthy volunteers in the first quarter of 2019 [21] 28 May 2019

Development History

Event Date Update Type Comment
26 Nov 2020 Other Chemical structure information added Updated 26 Nov 2020
28 Sep 2020 Phase Change - No development reported No recent reports of development identified for preclinical development in Pancreatic-cancer in Sweden (PO) Updated 28 Sep 2020
10 Jul 2020 Regulatory Status Swedish Medical Products Agency approves clinical trial application for KAND 567 in COVID-2019 infections Updated 16 Jul 2020
02 Jul 2020 Phase Change - II Phase-II clinical trials in SARS-COV-2 acute respiratory disease (Combination therapy) in Sweden (PO) (EudraCT2020-002322-85) Updated 27 Aug 2020
28 Jun 2020 Phase Change - No development reported No recent reports of development identified for phase-I development in Autoimmune-disorders in Netherlands (PO) Updated 28 Jun 2020
28 Jun 2020 Phase Change - No development reported No recent reports of development identified for phase-I development in Cancer in Netherlands (PO) Updated 28 Jun 2020
28 Jun 2020 Phase Change - No development reported No recent reports of development identified for phase-I development in Cancer-pain in Netherlands (PO) Updated 28 Jun 2020
15 Jun 2020 Phase Change - Preclinical Preclinical trials in Spinal cord injuries in Sweden (unspecified route) [2] Updated 22 Jun 2020
15 Jun 2020 Scientific Update Pharmacodynamics data from preclinical trial in Spinal cord injuries released by Kancera [2] Updated 22 Jun 2020
15 Jun 2020 Trial Update Kancera plans a phase II trial for SARS-COV-2 acute respiratory disease (PO, Capsule) [2] Updated 22 Jun 2020
15 May 2020 Regulatory Status Kancera submits application for phase II trial for Hyperinflammation in viral infections to Swedish Medicines Agency [3] Updated 22 May 2020
28 Apr 2020 Phase Change - No development reported No recent reports of development identified for preclinical development in Breast-cancer in Sweden (PO) Updated 28 Apr 2020
06 Mar 2020 Regulatory Status Kancera announces intention to submit application to start phase II trial for Myocardial infarction during second quarter of 2020 [5] Updated 17 Mar 2020
06 Mar 2020 Scientific Update Final adverse events and pharmacokinetics data from a phase Ib trial in Myocardial infarction released by Kancera [5] Updated 17 Mar 2020
05 Feb 2020 Regulatory Status Kancera received approval from the Finnish Medicines Agency Fimea and the Ethics Committee to start the final part of the phase Ib program for Myocardial infarction for KAND 567 [12] Updated 25 Feb 2020
04 Dec 2019 Scientific Update Immunogenicity data from a phase Ib trial in Healthy volunteers released by Kancera [13] Updated 26 Dec 2019
26 Nov 2019 Trial Update Kancera plans a phase IIa trial for Myocardial infarction (IV) (PO) in the second quarter of 2020 [14] Updated 06 Dec 2019
23 Aug 2019 Regulatory Status Kancera submits supplemental dosing strategy for the continued implementation of the study to Swedish Medical Products Agency in August 2019 (9273407;9273422) Updated 10 Sep 2019
23 Aug 2019 Patent Information Kancera has pending patent applications for KAND 567 in undisclosed territories outside Sweden [6] Updated 28 Aug 2019
23 Aug 2019 Scientific Update Interim pharmacokinetics and adverse events data from a phase Ib trial in Healthy volunteers released by Kancera [6] Updated 28 Aug 2019
04 Jun 2019 Phase Change - I Phase-I clinical trials in Myocardial infarction (In volunteers) in Finland (IV) [14] Updated 06 Dec 2019
04 Jun 2019 Phase Change - I Phase-I clinical trials in Myocardial infarction (In volunteers) in Sweden (IV) [7] Updated 26 Jun 2019
24 May 2019 Trial Update Kancera plans a phase Ib trial in healthy volunteers in Sweden, in June 2019 (IV) [11] Updated 26 Jun 2019
24 May 2019 Regulatory Status Medical Products Agency approves application for phase Ib trial of KAND 567 in healthy volunteers [11] Updated 28 May 2019
09 Feb 2019 Scientific Update Efficacy data from phase Ia trial in Healthy volunteers released by Kancera [17] Updated 13 Feb 2019
09 Feb 2019 Trial Update Kancera completes a phase Ia pharmacokinetic trial in Healthy volunteers [17] Updated 13 Feb 2019
01 Jan 2019 Scientific Update Preclinical adverse events data for intravenous KAND 567 released by Kancera [11] Updated 28 May 2019
23 Nov 2018 Regulatory Status Kancera plans to file regulatory application with the Medical Products Agency for a phase Ib trial in healthy volunteers in the first quarter of 2019 [21] Updated 28 May 2019
23 Nov 2018 Phase Change - Preclinical Preclinical trials in Myocardial infarction in Sweden (IV) [21] Updated 29 Mar 2019
23 Nov 2018 Regulatory Status Kancera plans to file regulatory application with the Japanese Pharmaceuticals and Medical Devices Agency for a IIa trial in Myocardial infarction in the second quarter of 2019 [21] Updated 28 Nov 2018
09 Jul 2018 Patent Information Kancera files for patent protection for KAND 567 in Sweden, prior to July 2018 [22] Updated 13 Jul 2018
09 Jul 2018 Trial Update Kancera plans a phase IIa trial for Cancer [22] Updated 13 Jul 2018
30 Jun 2018 Phase Change - Preclinical Preclinical trials in Cardiovascular disorders (Cardiovascular inflmmation) in Sweden (PO) [21] Updated 28 Nov 2018
28 Feb 2018 Scientific Update Pharmacokinetics, pharmacodynamics and adverse events data from a phase Ia trial in Cancer released by Kancera [18] Updated 28 Feb 2018
28 Feb 2018 Trial Update Kancera in collaboration with Karolinska Institutet plans a clinical trial in Cancer [18] Updated 28 Feb 2018
20 Feb 2018 Trial Update Kancera plans clinical trials for myocardial infarction and Lymphoma [19] Updated 22 Feb 2018
14 Sep 2017 Licensing Status Kancera enters into development and manufacturing agreement with Racipharm for KAND 567 in the treatment of Cancer pain [1] Updated 20 Sep 2017
31 May 2017 Phase Change - I Phase-I clinical trials in Cancer in Netherlands (PO) (Kancera pipeline, December 2017) Updated 08 Dec 2017
31 May 2017 Phase Change - I Phase-I clinical trials in Autoimmune disorders in Netherlands (PO) [15] Updated 04 Dec 2017
31 May 2017 Phase Change - I Phase-I clinical trials in Cancer pain in Netherlands (PO) [15] Updated 04 Dec 2017
30 Apr 2017 Regulatory Status Kancera applies to the relevant authorities in the Netherlands for authorization for clinical trials (Kancera pipeline, December 2017) Updated 07 Dec 2017
31 Mar 2016 Phase Change - Discontinued(Preclinical) Discontinued - Preclinical for Multiple myeloma in United Kingdom prior to this date (PO) Updated 15 Aug 2016
31 Mar 2016 Phase Change - Preclinical Preclinical trials in Cancer pain, Breast cancer and Pancreatic cancer in Sweden prior to this date (PO) Updated 15 Aug 2016
31 Dec 2006 Phase Change - Preclinical Preclinical trials in Multiple myeloma in United Kingdom (PO) Updated 15 Aug 2016

References

  1. Recipharm and Kancera collaborate to manufacture clinical trial supply.

    Media Release
  2. Kancera's drug candidate KAND567 has a positive effect on mobility in a preclinical model of spinal cord injury.

    Media Release
  3. Kancera applies for a Phase II study with KAND567 in covid-19 patients.

    Media Release
  4. KAND567 Versus Placebo in Subjects Hospitalized with COVID-19. A Phase II, Randomized, 2-Arm Parallel-Group, Double-blind Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics

    ctiprofile
  5. Kancera reports positive results from the final part of the phase Ib program for KAND567 .

    Media Release
  6. Kancera: Interim report for the second quarter 2019, 1 January - 30 June 2019.

    Media Release
  7. Kancera announces start of clinical Phase Ib study of KAND567.

    Media Release
  8. A supplementary phase 1b study to evaluate safety, tolerance and exposure of KAND567 administered intravenously in healthy subjects

    ctiprofile
  9. Kancera announces positive interim results and a minor delay in ongoing Phase Ib clinical study of KAND567.

    Media Release
  10. Kancera develops the dosing strategy for KAND567 which means an added delay of the phase 1b study .

    Media Release
  11. INTERIM REPORT FOR THE FIRST QUARTER 2019, 1 January - 31 March 2019.

    Media Release
  12. Kancera has received approval to start the final part of the phase Ib program for KAND567.

    Media Release
  13. Kancera reports in-depth analysis of the Phase Ib program with KAND567, showing the desired effect on the human immune system.

    Media Release
  14. Interim report for the third quarter 2019, 1 January - 30 September 2019.

    Media Release
  15. Kancera performs the second partial payment for the Fractalkine project.

    Media Release
  16. A phase Ia trial to evaluate the safety, tolerability and pharmacokinetic properties of KAND-567 in Healthy Subjects

    ctiprofile
  17. Kancera reports results from analyses of the Fractalkine system in lymphoma patients' immune cells.

    Media Release
  18. Kancera reports results from clinical Phase I study and strategy for continued development of KAND567.

    Media Release
  19. Kancera AB (publ) Reports Positive Results from a Phase I Study in Healthy Subjects With its Lead Immunoregulating Drug Candidate KAND567.

    Media Release
  20. Kancera's research will be highlighted at this year's largest conference on cardiovascular diseases.

    Media Release
  21. INTERIM REPORT FOR KANCERA AB (publ) 1st January - 30th September 2018.

    Media Release
  22. A new patent application from Kancera lays the foundation for the development of additional drug candidates in the Fractalkine project.

    Media Release
Back to top